From where I stand, Lenacapavir could revolutionise HIV treatment in Guyana and across the Caribbean. Imagine this: just two injections a year—no more daily pills, no more daily reminders of stigma. For communities battling adherence issues, social barriers, and healthcare gaps, Lenacapavir represents a bold leap forward in our mission to end AIDS by 2030.

This long-acting injectable could boost viral suppression, curb transmission, and empower patients with more freedom and dignity. It’s especially promising for those with drug-resistant HIV, offering hope where options are currently limited.

But with every breakthrough comes a reality check. Cost, storage demands, and the need for specialised clinical training may slow its roll-out. And let’s not forget: fewer visits may also mean missed opportunities to catch resistance or complications early.

Still, the potential is undeniable. If we act strategically—through regional cooperation, smart procurement, and strong policy backing, Lenacapavir could be the shot that changes everything for HIV care in the Caribbean.